

Index

A

AC. *See* Adenylate cyclase
Adenylate cyclase (AC), sperm signaling, 278
ADPKD. *See* Autosomal-dominant polycystic kidney disease
Agouti-related peptide (AgRP), 259
AgRP. *See* Agouti-related peptide
AHI1, 351
AKAPs. *See* Protein kinase A–anchoring proteins
AKT, cilia signaling, 128–131
AKT1, 265
ALR13b, 232
Alstrom syndrome, 230, 257, 259–260, 355
AMPK, 265
ANKS6, 225, 229
Annulus
 migration, 119–121
 structure, 119
Arl3, 101
ARL13B, 101, 155
Autosomal-dominant polycystic kidney disease (ADPKD)
 cilia-dependent cyst activation
 animal models, 244–245
 cyst formation in other ciliopathies, 247
 PC1 regulation, 251
 physiological function, 245
 prospects for study, 251–252
 signaling
 β 1-integrin, 249
 cyclic AMP, 248
 Hedgehog signaling, 245, 247–248
 Lkb1, 248
 mitogen-activated protein kinase, 249
 mTOR, 248–249
 platelet-derived growth factor, 249
 ciliary dysfunction in cyst formation, 243–244
 gene mutations, 242–244
 mechanosensor hypothesis for polycystins in cilia, 249–251
 overview, 241
Axoneme
 central pair structure, 12–13
 dynein
 arms
 assembly in axonemal superstructure, 35–36
 composition, 32–34, 37

 cytoplasmic preassembly and trafficking of complexes, 34–35
 dysfunction consequences, 38–39
 motor function and regulation, 36, 38
 prospects for study, 39
 bending mechanism, 11–12
 intermediate chain and light chain complexes, 12
 isoform distribution, 12
 nucleotide-induced structural change, 5
 structure and arrangement, 4, 10–11
 electron microscopy, 8–9
 exceptional motile cilia, 6–8
 microtubule doublet
 linkers, 13
 structure, 3, 6–10
 9+2 structure, 3, 6, 9, 126
 prospects for study, 13–14
 radial spoke structure, 12–13
 structural overview, 1–6

B

Bardet–Biedl syndrome (BBS), 230, 247, 257, 259–260, 354–355
Basal body (BB)
 amplification, 184–186
 assembly
 dynamics, 185, 187
 evolution, 188
 molecular control, 187–188
 ciliary beat orientation, 191–192
 docking and ciliogenesis
 actin cytoskeleton role, 188–190
 assembly, 190–191
 docking, 190
BBS. *See* Bardet–Biedl syndrome
BBS10, 264
BBS12, 264
BBSome, intraflagellar transport protein roles in transport, 79–80
 β -Arrestin, 168, 174
 β 1-Integrin, cilia-dependent cyst activation signaling, 249
Bitter taste receptor (T2R), 175
Bld10p, 48
BLD12, 48
BMPs. *See* Bone morphogenetic proteins
Bone morphogenetic proteins (BMPs), cilia signaling, 134–135

C

- CA. *See* Central apparatus
cAMP. *See* Cyclic AMP
CapZIP, 190
CatSper, sperm signaling, 277–278, 281, 284
Cby1, 93, 103
CCDC14, 302
CCDC39, 35
CCDC40, 35
CCDC78, 188
CCDC103, 35
CCDC151, 302, 372
CCNO, multiciliated cell specification and differentiation regulation, 184–185, 188
Cdc123, 93
Cdc41, 93
CDH23, 350
CDHR1, 348
Celsr, 189
Central apparatus (CA)
 assembly, 47–49
 composition, 45–47
 functions, 49–51
 pathology, 51–52
 prospects for study, 52
 structure, 43–45
Central pair (CP), structure, 12–13
Centriole
 cell-cycle changes, 111–112
 cilium relationship, 112
 elongation before axoneme assembly, 112, 114
 hedgehog response regulation, 149
 sperm
 giant centrioles, 115–117
 specialized centrioles, 115
Centriole and spindle-associated protein (CSAP), 23
CEP63, 187–188
CEP78, 350
Cep83, 93–94, 102
Cep89, 93
Cep123, 93
CEP162, 121–122, 187
CEP164, 83–94, 102, 190
CEP250, 350
Cep290, 95, 97, 104, 118, 121, 227
Cerl2, 207–209
CFAP54, 52
CG42699, 122
CHD. *See* Congenital heart disease
CIB2, 350
Cilia-dependent cyst activation. *See* Autosomal-dominant polycystic kidney disease
Ciliary nephronophthisis (NPHP), 95–97, 102
CLRN1, 348–350
C-MYB, multiciliated cell specification and differentiation regulation, 184
CNGK. *See* Cyclic nucleotide-gated potassium channel
Cogan syndrome, 227–228
Congenital heart disease (CHD)
 cilia and signaling
 cell polarity specification and polarized cell migration, 332–333
 ciliopathy-associated congenital heart disease, 335–336
 development role, 326–328
 gene mutations, 334–335
 left–right patterning, 333–334
 Sonic hedgehog, 329
 transforming growth factor- β , 332
 Wnt, 329, 332
 development of cardiovascular system, 324–325
 four-chamber perturbation, 324, 326
 overview, 323–324
 prospects for study, 336–337
CP. *See* Central pair
CP110, 93, 150, 190–191
CPC1, 46–47, 51
CPLANE, 150
Craniofacial ciliopathies. *See also specific diseases*
 ciliary dysfunction sensitivity, 310
 development
 cranial neural crest cells, 313–315
 facial ectoderm, 315–316
 neuroectoderm, 315
 overview, 312–313
 pharyngeal endoderm, 316
 signaling in cilia
 Hedgehog signaling, 316–318
 Wnt, 318–319
 overview, 309–310
 pairwise combination of phenotypes, 311
 prospects for study, 319–320
 tables of diseases, 312–313
CSAP. *See* Centriole and spindle-associated protein
Cyclic AMP (cAMP)
 cilia-dependent cyst activation signaling, 248
 sperm signaling, 278
Cyclic nucleotide-gated potassium channel (CNGK), sperm signaling, 276, 279–280
Cyclin D1, 292

D

- DAAM1, 188, 190
DEUP1, 187–188
Dishevelled, 189, 192–193, 205
Diversin, 189
DNAH1, 302
DNAH5, 302
DNAH11, 303
DNAJB13, 121

Dynein, axoneme
arms
assembly in axonemal superstructure, 35–36
composition, 32–34, 37
cytoplasmic preassembly and trafficking of
complexes, 34–35
dysfunction consequences, 38–39
motor function and regulation, 36, 38
prospects for study, 39
bending mechanism, 11–12
intermediate chain and light chain complexes, 12
isoform distribution, 12
nucleotide-induced structural change, 5
structure and arrangement, 4, 10–11
DYXC1, 302

E

EGF *See* Epidermal growth factor
EHD1, 93
EHD3, 93
Ellis–van Revald syndrome, 156
Epidermal growth factor (EGF), cilia signaling, 133
EVC, 156
Evolution
basal body, 188
cilia
eukaryote divergence
evolution after, 374–375
evolution before, 375–377
last eukaryotic common ancestor, 370–371
motility, 372–373
overview, 369–370
trafficking, assembly, and signaling, 373–374
tubulins, 371–372
radial spoke, 60–62

F

FAP59, 35
FAP172, 35
FAP221, 51
FBB18, 34
Fbf1, 93
FGF *See* Fibroblast growth factor
Fibroblast growth factor (FGF), cilia signaling, 133
FLTP, 190
FSCN2, 348
FTO, 258, 263–264

G

GC. *See* Guanylate cyclase
Gdf1, 207
GEMC1, multiciliated cell specification and
differentiation regulation, 183–184

GLI1, 151, 153
GLI2, 151, 153, 155
GLI3, 153, 155, 317
GPCRs. *See* G-protein-coupled receptors
G-protein-coupled receptors (GPCRs). *See also specific ligands*
cholangiocyte cilia signaling, 172–173
cilia localization impact, 175–176
ciliary localization, 168
hedgehog signaling modulation, 171
motile cilia signaling, 175
neuron cilia signaling, 173–175
olfactory receptor signaling, 167–170
opsin signaling, 169–171
overview of signaling, 165–167
renal cilia signaling, 171–172
Guanylate cyclase (GC), sperm signaling, 274, 276, 278–279

H

HARS, 350
HCN. *See* Hyperpolarization-activated and cyclic
nucleotide-gated channel
HDAC6, 20
Hedgehog signaling. *See also specific proteins*
centriole and basal body protein regulation
of response, 149
cilia
cell lineage determination of primary cilia
in mouse embryo, 156–158
cell-type-specific differences and signaling
modulation, 155–156
gene mutation effects, 147–149, 154–155
pathway switching control, 153–154
requirement for signaling in all vertebrate tissues,
150–151
cilia-dependent cyst activation, 245, 247–248
craniofacial ciliopathies, 316–318
developmental patterning, 144–145
G-protein-coupled receptors in signaling
modulation, 171
intraflagellar transport protein regulation, 79, 154–155
peripheral cilia in metabolic regulation and obesity,
264–265
Hepatocyte growth factor (HGF), cilia signaling, 133
HGF. *See* Hepatocyte growth factor
HSP40, 60, 62
Hydin, 46–47
Hyperpolarization-activated and cyclic nucleotide-
gated channel (HCN), sperm signaling,
276–277

I

IFT. *See* Intraflagellar transport
IGF-1. *See* Insulin-like growth factor 1

- Inpp5e, 94
Insulin-like growth factor 1 (IGF-1), cilia signaling, 132–133
Intraflagellar transport (IFT)
 history of study, 73–75
 IFT-A complex
 architecture, 82
 protein functions in complex formation and stability, 82–83
 IFT-B complex
 architecture
 IFT-B1, 75–76
 IFT-B2, 76–78
 protein functions
 BBSome transport, 79–80
 formation and stability, 78
 Hedgehog signaling regulation, 79, 154–155
 membrane protein sorting at cilium, 80–81
 transport of motility factors, 78–79
 tubulin dimer and microtubule binding, 81–82
 turnaround at ciliary tip, 80
 motor protein interactions with IFT complexes, 84–85
 overview, 71–73, 127
 photoreceptor sensory cilia, 343, 347
 prospects for study, 85
 protein nomenclature, 74
 Sonic hedgehog signal transduction in mouse embryo, 145–146, 149
 train formation and IFT-A/IFT-B complex interactions, 83
- INVS*, 225
IQCB1, 227
IRX3, 264
- J**
JBTS4, 228
JBTS6, 228
JBTS7, 228
JBTS10, 230
Joubert syndrome, 228, 247, 353
- K**
KAP3, 145
Kif17, 101
KIF3, 145, 149
Kinesin-1, 20
Kinesin-2, 127
KISS1R, 175
KLP1, 46–47
- L**
Last eukaryotic common ancestor. *See* Evolution
LCA5, 348
- Left–right asymmetry
 cilia-driven fluid flow in mouse embryo, 203–205
 clockwise rotation of mouse node cilia, 206–207
 congenital heart disease and cilia role in patterning, 334
 fluid flow in symmetry breaking
 calcium flux, 208
 Cerl2 messenger RNA asymmetry in flow sensing, 208–209
 immotile colia as flow sensor, 207–208
 overview, 203
 planar cell polarity, 205
 prospects for study, 209
- Leptin, 258–259, 262
LKB1, 248, 265
LRP2, 334
LRRC50, 3
- M**
MAK, 348
MAPK. *See* Mitogen-activated protein kinase
MC4R. *See* Melanocortin 4 receptor
MCC. *See* Mucociliary clearance; Multiciliated cell
MCIDAS, multiciliated cell specification and differentiation regulation, 183–184, 187
MCKD. *See* Medullary–cystic kidney disease
MEC-17/ATAT1, 18, 20
Meckel–Gruber syndrome (MKS), 229–230, 247, 353–354
Medullary–cystic kidney disease (MCKD), 214, 223
Melanocortin 4 receptor (MC4R), 258–259
Microtubule doublet (MTD)
 linkers, 13
 structure, 3, 6–10
Mitogen-activated protein kinase (MAPK)
 cilia-dependent cyst activation signaling, 249
 cilia signaling, 128–130
MKS. *See* Meckel–Gruber syndrome
MKS complex, 95, 103
MORM syndrome, 355
MTD. *See* Microtubule doublet
mTOR, cilia-dependent cyst activation signaling, 248–249
MUC1, 223
Mucociliary clearance (MCC)
 cilia
 beat frequency, 299–300
 regulation, 299–300
 structure, 297–299
 components
 mucous layer, 295, 297
 overview, 295–296
 periciliary layer, 297
 surfactant, 297
 measurement

- overview, 300–301
 - variables, 301–302
 - overview, 291–292
 - primary ciliary dyskinesia, 302–303
 - prospects for study, 303
 - respiratory tract
 - cell types in lower respiratory tract
 - ciliated cells, 294–295
 - secretory cells, 294
 - development, 292
 - structure, 293–294
 - Multiciliated cell (MCC)
 - ciliary beat orientation
 - basal body organization, 191–192
 - beat regulation, 194–195
 - hydrodynamic forces, 194
 - polarization by planar cell polarity pathway, 192–194
 - ciliogenesis. *See* Basal body
 - mammalian epithelia, 182
 - overview, 181–182
 - prospects for study, 195
 - specification and differentiation
 - downstream effectors, 184–185
 - GEMC1 regulation, 183–184
 - MCIDAS regulation, 183–184
 - Notch inhibition, 182–183
 - MYO7A, 350
- N**
- NDK5, 60–61
 - NEK8, 229
 - Nephronophthisis (NPHP)
 - cilia-dependent cyst activation, 247
 - clinical presentation, 224–225
 - diagnosis, 226
 - differential diagnosis, 226
 - extrarenal manifestations
 - Alstrom syndrome, 230
 - Bardet–Biedl syndrome, 230
 - Cogan syndrome, 227–228
 - congenital heart disease, 229
 - Joubert syndrome, 228
 - liver involvement, 228–229
 - Meckel–Gruber syndrome, 229–230
 - oral-facial-digital syndrome type 1, 230
 - overview, 226–227
 - Senior–Løken syndrome, 227
 - skeletal phenotypes and polydactyly, 229
 - Usher syndrome, 230–231
 - genetics, 231
 - genotype–phenotype correlations, 215–223
 - model organisms, 231–232
 - overview, 214, 223
 - pathology, 225–226
 - therapy and prognosis, 225
 - type 1 disease, 231
 - type 2 disease, 224
 - Neuropeptide Y (NPY), 173
 - NF- κ B. *See* Nuclear factor- κ B
 - NHE. *See* Sodium/proton exchanger
 - Nmyc, 292
 - Nodal, 207–208
 - Notch, multiciliated cell specification and differentiation regulation, 182–183
 - NPHP. *See* Ciliary nephronophthisis; Nephronophthisis
 - NPHP1, 228, 231
 - NPHP2, 228–229
 - NPHP3, 228–229, 232, 244
 - NPHP4, 189, 228, 231
 - NPHP5, 227
 - NPHP6, 227
 - NPHP7, 231
 - NPHP9, 244
 - NPY. *See* Neuropeptide Y
 - Nubp1, 190
 - Nuclear factor- κ B (NF- κ B), cilia signaling, 134
- O**
- Obesity
 - ciliopathies with obesity
 - conditional mutants in mice, 260
 - LEPR mutations, 262
 - mouse models, 260–261
 - neuron involvement, 260, 262–263
 - overview, 259–260
 - genetic predisposition, 258
 - leptin–melanocortin pathway regulation of energy homeostasis, 258–259
 - pathophysiology, 258
 - peripheral cilia in metabolic regulation and obesity, 264–265
 - prospects for study, 265–266
 - RPBRIP1L studies, 263–264
 - ODA proteins, 34
 - ODF2, 191
 - Odf2, 93
 - OFD1. *See* Oral-facial-digital syndrome type 1
 - Olfactory receptor, signaling, 167–170
 - Opsins, vision signaling, 169–171
 - Oral-facial-digital syndrome type 1 (OFD1), 93, 150, 230, 355–356
- P**
- Patched1, 127–128, 143, 153–154
 - PCD. *See* Primary ciliary dyskinesia
 - PCDH15, 350
 - PCP. *See* Planar cell polarity

Pde6d, 101
PDGF. *See* Platelet-derived growth factor
PF proteins, 45–50
Phosphoinositide 3-kinase (PI3K), cilia signaling, 128–130
Phospholipase C (PLC), cilia signaling, 129–130
Photoreceptor sensory cilia (PSC)
 functional overview, 341–342
 outer segment components, 343
 protein transport
 intraflagellar transport, 343, 347
 membrane protein transport, 347
 photoactivated protein diffusion, 347
 retinal ciliopathies
 Alstrom syndrome, 355
 Bardet–Biedl syndrome, 354–355
 genetic modifiers, 351–352, 355–356
 Joubert syndrome, 353
 Meckel–Gruber syndrome, 353–354
 MORM syndrome, 355
 nonsyndromic retinal degeneration
 genes, 344–346
 sensory function defects, 349–350
 structural disruption, 348–349
 oral-facial-digital syndrome, 355–356
 phenotypic spectrum, 355–356
 Senior–Løken syndrome, 353
 short-rib thoracic dysplasia, 355
 Usher syndrome, 350, 353
 structure, 342–343
PI3K. *See* Phosphoinositide 3-kinase
PKA. *See* Protein kinase A
PKD1, 232, 242–243
PKD1, 349, 374
PKD2, 232, 242–243
PKD2, 208, 349, 374
Pkd11, 208
Pkd2l1, 175
Planar cell polarity (PCP), 189, 192–194, 205
Platelet-derived growth factor (PDGF)
 cilia-dependent cyst activation signaling, 249
 cilia signaling, 129–132
PLC. *See* Phospholipase C
PLK4, 187
Polycystic kidney disease. *See* Autosomal-dominant polycystic kidney disease
Prickle, 189, 205
Primary ciliary dyskinesia (PCD)
 dynein arm dysfunction, 39
 gene mutations, 302–303
PROM1, 348
Protein kinase A (PKA), 153, 173
Protein kinase A–anchoring proteins (AKAPs), RSP3 as, 60
PRPH2, 348, 356
PSC. *See* Photoreceptor sensory cilia

R

Radial spoke (RS)
 assembly, 62–63
 evolution, 60–62
 functions
 axoneme stability maintenance, 65–66
 chemical signaling, 65
 mechanical feedback and coordination
 of molecular motors, 64–65
 planar waveform generation, 64
 morphology, 58
 mutants, 63
 outer doublet connections, 63
 periodicity, 58
 prospects for study, 66
 proteins
 Chlamydomonas, 58–60
 organization, 60
 structure, 12–13, 59
Receptor tyrosine kinase signaling. *See specific ligands*
ROM1, 348
RP1, 348, 356
RPBRIP1L, 263–264
Rpgrip1l, 96–97, 103–104, 257–258
RPIL1, 348
RS. *See* Radial spoke
RSPH1, 302–303
RSPH19, 302
RSPH4A, 302

S

SAS4, 149
SAS-6, 187
Senior–Løken syndrome (SLS), 227, 353
SHH. *See* Sonic hedgehog
Short-rib thoracic dysplasia (SRTD), 355
SIRT2, 20
Slo3, 283
SLS. *See* Senior–Løken syndrome
SMADs, cilia signaling, 134–136
SMO. *See* Smoothened
Smoothened (SMO), 127–128, 143, 151, 247, 264
Sodium/proton exchanger (NHE), sperm signaling, 276, 280
Sonic hedgehog (SHH)
 cilia signaling, 127–128
 congenital heart disease and cilia signaling, 329
 craniofacial ciliopathies, 316–318
 developmental patterning, 145
 intraflagellar transport and signal transduction
 in mouse embryo, 145–146, 149
Sox9, 292
SPAG1, 302
Spag16L, 52
Spag17, 51

- Sperm
- annulus, 119–121
 - guidance to egg, 271–273
 - signaling
 - fish sperm, 279–280
 - mammalian sperm
 - calcium clearance, 283–284
 - CatSper, 281, 283
 - compartmentalization and supramolecular structures, 284–285
 - intracellular pH regulation, 284
 - mouse versus human sperm, 282
 - overview, 280
 - potassium channels, 283
 - prospects for study, 285
 - sea urchin sperm
 - adenylate cyclase, 278
 - amplification, 278–279
 - CatSper, 277–278
 - cyclic nucleotide-gated potassium channel, 276, 279
 - guanylate cyclase, 274, 276, 278–279
 - hyperpolarization-activated and cyclic nucleotide-gated channel, 276–277
 - overview, 274–275
 - recovery, 278
 - sodium/proton exchanger, 276
 - specialized centrioles and cilia, 115–117
- SRTD. *See* Short-rib thoracic dysplasia
- SSTR3, 174–175
- SUFU, 158
- T**
- T2R. *See* Bitter taste receptor
- TAK1, 134
- Talpid3, 150
- Tctex-1, 133
- TF. *See* Transition fiber
- TGF- β . *See* Transforming growth factor β
- TGR5, 173
- Tie receptors, 133
- Transforming growth factor β (TGF- β)
 - cilia signaling, 133–137
 - congenital heart disease and cilia signaling, 332
- Transition fiber (TF)
 - architecture, 92–93
 - ciliary gate diseases, 102–104
 - functions, 93–94
 - overview, 91–92
- Transition zone (TZ)
 - architecture, 94–96
 - ciliary gate diseases, 102–104
 - ciliogenesis role, 97–98
 - cilium compartmentalization, 114–115
 - migration
 - centriole formation and ciliogenesis, 112–113
 - cytoplasmic ciliogenesis
 - annulus in mammalian sperm, 119–121
 - axoneme exposure to cytoplasm, 117–118
 - ciliary gate elasticity, 122
 - Drosophila* spermatids, 118–119
 - motor-driven versus exchange-driven migration, 121
 - Drosophila* spermatocytes, 117–119
 - overview, 91–92
 - protein trafficking role
 - membrane proteins, 100–102
 - soluble proteins, 98–100
- TTBK2, 94, 150, 190
- TTC8, 355
- TTL. *See* Tubulin tyrosine ligase
- Tubulin
 - cilia evolution, 371–372
 - posttranslational modification
 - acetylation of K40
 - cilia disassembly role, 20
 - motor-driven motility role, 20–21
 - overview, 17–20
 - detyrosination, 21
 - glutamylation
 - ciliary assembly and microtubule stability role, 23
 - motility role, 22–23
 - negative length regulation of cilia, 23–24
 - overview, 21–22
 - glycation, 24–25
 - overview, 17
 - prospects for study, 25
- Tubulin tyrosine ligase (TTL), 21–25
- TULP1, 348
- TULP3, 83, 154–155, 158
- TZ. *See* Transition zone
- U**
- UMOD, 223
- Unc119b, 101
- USH1C, 350
- USH1G, 350
- USH2A, 348–350
- Usher syndrome, 230–231
- V**
- Vangl, 189, 205
- Vangl1, 192
- Vangl2, 192
- W**
- WNT
 - cilia signaling, 128
 - congenital heart disease and cilia signaling, 329, 332
 - craniofacial ciliopathies, 318–319